St. Jude Medical (NYSE:STJ) has launched its latest product on the European market. The company announced that it has received the CE Mark for its Prodigy Chronic Pain System with Burst Technology and can now market and sell the product on the continent.
St. Jude Medical claims that Prodigy is "the first and only implantable neuromodulation system that delivers burst stimulation." It is intended to reduce pain and reduce parasthesia, a tingling sensation, in patients suffering from chronic pain. It utilizes spinal cord stimulation to achieve its effects.
In the press release announcing the news, the company quoted its Group President Eric Fain as saying that Prodigy "is a great example of our approach for innovative and alternative ways to provide relief to patients suffering from chronic pain, including those who have exhausted other treatment options or who may have lost effective therapy using traditional tonic stimulation."
Eric Volkman has no position in St. Jude Medical. Nor does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.